Lupila-D Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Ilaprazole 10 mg, designed for the management of gastrointestinal disorders associated with acid reflux and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric emptying and enhances gastrointestinal motility, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort related to delayed gastric emptying. Ilaprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, effectively reducing gastric acidity and promoting mucosal healing in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of Domperidone and Ilaprazole in Lupila-D Capsule provides comprehensive relief from acid-related gastrointestinal symptoms and improves patient quality of life. This combination is particularly beneficial in patients requiring both acid suppression and enhanced gastric motility. Lupila-D Capsule should be used under medical supervision, with dosage and duration tailored to individual patient needs. Caution is advised in patients with cardiac arrhythmias or electrolyte imbalances due to Domperidone’s potential QT prolongation effect. It is contraindicated in hypersensitivity to either component and should be avoided in patients with prolactin-secreting tumors.